Adamis Pharmaceuticals Corp License Agreements
12 Contracts & Agreements
- First Amendment to Exclusive License Agreement dated November 9, 2021 between the Company and Matrix Biomed, Inc (Filed With SEC on March 31, 2022)
- Development, License and Commercialization Agreement dated as of May [10], 2016, between the Company and Watson Laboratories, Inc (Filed With SEC on August 15, 2016)
- License Agreement dated January 2, 2008, with Wisconsin Alumni Research Foundation (Filed With SEC on July 7, 2011)
- License Agreement dated January 26, 2007, with Wisconsin Alumni Research Foundation (Filed With SEC on July 7, 2011)
- License Agreement dated January 26, 2007, with Wisconsin Alumni Research Foundation (Filed With SEC on July 7, 2011)
- License Agreement between Adamis, the Regents of the University of California and Dana-Farber Cancer Institute, Inc (Filed With SEC on July 7, 2011)
- LICENSE AGREEMENT between CONRAD, Eastern Virginia Medical School and Biosyn, Inc., a subsidiary of Cellegy Pharmaceuticals, Inc. (Filed With SEC on April 2, 2007)
- First Amended and Restated Exclusive License Agreement For Tostrex Between STRAKAN INTERNATIONAL LIMITED And Cellegy Pharmaceuticals, Inc. Confidential (Filed With SEC on March 31, 2006)
- FIRST AMENDED AND RESTATED EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT FOR RECTOGESIC Between STRAKAN INTERNATIONAL LIMITED And Cellegy Pharmaceuticals, Inc. Confidential (Filed With SEC on March 31, 2006)
- LICENSE AGREEMENT between CROMPTON CORPORATION and BIOSYN, INC. (Filed With SEC on March 31, 2005)
- PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENTEXCLUSIVE COVER PAGE (Filed With SEC on March 31, 2005)
- EXCLUSIVE LICENSE AGREEMENT FOR TOSTREX BETWEEN STRAKAN INTERNATIONAL LIMITED AND CELLEGY PHARMACEUTICALS, INC. CONFIDENTIAL (Filed With SEC on August 10, 2004)
